摘要
目的观察雷莫司琼预防顺铂所致恶心呕吐反应的作用及不良反应。方法采用随机自身对照方法对43例接受大剂量顺铂联合化疗的恶性肿瘤病人使用雷莫司琼进行止吐治疗并与恩丹西酮作对照,于化疗第一周期或第二周期使用雷莫司琼止吐,同一病人于另一周期使用恩丹西酮作自身对照。结果雷莫司琼组对预防化疗后24小时内急性恶心呕吐有效率高于对照组(P<0.05),预防化疗后2～3天出现的恶心有效率高于对照组,预防化疗后2～4天出现的呕吐有效率高于对照组(P<0.05～0.01),雷莫司琼组恶心和呕吐持续时间均短于对照组,两组平均恶心持续时间分别为50.22和87.80小时(P<0.01)平均呕吐持续时间分别为31.15和48.40小时(P<0.05),两组不良反应相近。结论雷莫司琼能有效预防大剂量顺铂所致的恶心呕吐反应,对于急性和延迟性呕吐反应均有较好疗效。
Objective To evaluate the effect of ramosetron in controlling nausea and vomiting induced by chemotherapy. Methods Forty-three patients undergoing cisplatin-based chemotherapy received ramosetron to control emesis. Ondansetron was used as self-control in the previous or next course of the chemotherapy in the same patient. Results The effective rate of acute nausea and vomiting during the first 24 hours in ramosetron group was significantly higher than that in ondansetron group (P< 0.05). The effective rate of nausea control in ramosetron group was higher than that in ondansetron group between day 2 to day 3 after chemotherapy, and the effective rate of vomiting control in ramosetron group was higher than that in ondansetron group between day 2 to day 4 after chemotherapy(P< 0.05～ 0.01). The average nausea and vomiting periods in ramosetron group was much shorter as compared to ondansetron group ( 50.22/ 87.80 and 31.15/ 48.40 hours respectively, P< 0.05～ 0.01). Conclusion Ramosetron is effective and superior to ondansetron in controlling of acute and delayed nausea and vomiting induced by cisplatin-based chemotherapy.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2005年第7期434-435,共2页
Cancer Research on Prevention and Treatment
关键词
雷莫司琼
顺铂
化疗/副作用
Ramosetron
Cisplatin
Chemotherapy/side-effect
